CD276 and neoplasm: Similarly, the combination of enoblituzumab, an anti-B7-H3 monoclonal antibody, and pembrolizumab (anti-PD-1) demonstrated an acceptable safety profile and anti-tumor activity in immune checkpoint inhibitor-naive patients [25].